Overview

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Status:
RECRUITING
Trial end date:
2029-08-03
Target enrollment:
Participant gender:
Summary
To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Alpelisib
pembrolizumab